{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-010065","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2026-02-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.277853+00:00","generated_at":"2026-05-16T04:53:23.752301+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Coherus enters Phase 1b combo trial with Janssen for tagmokitug in mCRPC","bullets":["Clinical supply agreement with Janssen to evaluate tagmokitug (anti-CCR8) plus pasritamig in mCRPC Phase 1b.","Coherus sponsors trial; Janssen supplies pasritamig. Both retain full commercial rights to their compounds.","Tagmokitug is an investigational cytolytic monoclonal antibody targeting CCR8; study to start in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-010065","json":"https://secwatch.observer/filing/0001104659-26-010065.json","markdown":"https://secwatch.observer/filing/0001104659-26-010065.md","text":"https://secwatch.observer/filing/0001104659-26-010065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926010065/0001104659-26-010065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000110465926010065/chrs-20260204x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:53:23.752301+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}